MPNmyelofibrosisPhiladelphia-negative chronic myeloproliferative neoplasmsruxolitinibmomelotinibfedratinibPalandri et al.
…iveness in reducing splenomegaly and controlling haematocrit in MPN, with a manageable safety profile. The frequency of dose adjust…